Eli Lilly profits surge on demand for weight-loss drugs

Coverage, in order

1. 13d ago
   first Financial Times Health UK mainstream

   Eli Lilly profits surge on demand for weight-loss drugs

   US drugmaker to raise its revenue outlook for the second time in three months

2. 13d ago
   
   WSJ Health mainstream

   Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound

   The pharmaceutical company’s third-quarter profit came in at $6.45 billion, or $7.22 a share, compared with $5.58 billion, or $6.21 a share, a year earlier.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.